3 min readNov 22, 2023

Neuromyelitis optica spectrum disorder (NMOSD) Market By Emerging Trends, Business Strategies and Competitive Landscape

The high prevalence of multiple sclerosis greatly influences the growth of the neuromyelitis optica spectrum disorder (NMOSD) market. The expected number of people with MS has increased to 2.8 million in 2020 globally. Clinical development for NMOSD has steadily grown lately; there are three ongoing pipeline drugs in late-stage development. It has been witnessed that the monoclonal antibody drugs segment is anticipated to hold the largest share in this market segment.

Data Bridge Market Research shows that the Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market was valued at USD 405.9 million in 2021 and is expected to reach USD 651.84 million by 2029, registering a CAGR of 6.10% during the forecast period of 2022 to 2029.

“ Increasing Monoclonal Antibody Drug Approvals Surge the Market Growth”

The growing monoclonal antibody drug approvals and increasing research and development activities by the market players for launching effective treatment options for patients with neuromyelitis optica spectrum disorder are also surging the market growth. For instance, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted market authorization to Horizon’s UPLINZA as a monotherapy in 2021. It is used for the treatment of adult patients having neuromyelitis optica spectrum disorder (NMOSD) who tested positive for anti-aquaporin-4 immunoglobulin G ( (AQP4-IgG+) antibodies. Thus, this factor boosts market growth.

What restraints the growth of the Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market?

“ High Cost of Neuromyelitis Optica Spectrum Disorder (NMOSD)”

The growing high costs associated with R&D activities and the cost associated with new drug development combined with the threat of failure and adverse effects will emerge as one of the main limitations for the market. Neuromyelitis optica spectrum disorder (NMOSD) needs complex drug development processes, necessitating much-advanced diagnostic and treatment equipment and tools. All these major factors impede the growth of the market.

To know more about the study, visit,

The Prominent Key Players Operating in the Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Include:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • Zydus Cadila (India)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K.)
  • Horizon Therapeutics PLC (Ireland)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • LEO Pharma A/S (Denmark)
  • Bausch Health Companies Inc. (Canada)
  • Aurobindo Pharma (India)
  • Lupin (India)

Browse More Reports:

Global Maternal Health Market

Global Clinical Trials Market

Global Dysphagia Market

Global Solid Tumors Market

Global Lice Treatment Market

Global Presbyopia Market

Global Physical Therapy Market

Global Medical Display Market

Global eHealth Market

U.A.E Aesthetics/Cosmetics Market

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decisionmaking process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475